Financing Stem Cell Therapy: Payment Plans and Medical Loans

Most clinics offer financing, and for a $15,000 cash-pay procedure that is often how the sale closes. Before you sign anything, it is worth understanding both the mechanics and the maths.

The common options

Medical credit cards. CareCredit and similar products are the most frequently offered. They typically run promotional interest-free periods of 6 to 24 months.

The critical detail is deferred interest. With most of these products, if any balance remains when the promotional period ends, interest is charged retroactively on the entire original amount from day one — not on the remaining balance. Standard rates on these cards are often in the high twenties. A $15,000 treatment with $500 left unpaid at month 24 can trigger several thousand dollars in back-dated interest.

Personal loans. Fixed rate, fixed term, from a bank, credit union or online lender. Rates depend on credit, commonly ranging from single digits to the low thirties. Less dramatic downside than deferred interest, and easier to compare honestly.

Clinic in-house plans. Terms vary enormously. Some are genuinely interest-free; others carry fees that function as interest. Ask for the APR in writing, not the monthly payment.

Home equity. Cheapest rates available, and the only option that puts your house at risk. We would think very hard before securing an experimental medical treatment against a home.

Retirement withdrawals. Early withdrawal typically triggers income tax plus a penalty, and permanently removes the compounding. The true cost is substantially higher than the amount withdrawn.

Read the terms for these five things

1. Deferred vs waived interest. Waived is fine. Deferred is the trap described above.
2. The APR, not the monthly payment. Clinics quote monthly payments because they sound small.
3. Origination fees, often 1–8% deducted from the loan.
4. Prepayment penalties.
5. What happens if the treatment does not work. In every case: nothing. The loan is independent of the outcome.

The question underneath the financing question

Financing is a tool. Whether to use it here depends less on the interest rate than on something the clinic will not raise with you.

For most of the conditions these treatments are sold for, the evidence of benefit is weak. In knee osteoarthritis — the single most commonly treated indication — a 2025 meta-analysis of randomised trials found that roughly 63% of the pain improvement at six months and about half at twelve months was attributable to contextual and placebo effects, with the cells contributing only a modest incremental benefit, and the certainty of evidence rated low.

Borrowing at 26% APR for a treatment where most of the measured effect may be placebo is a different financial decision than borrowing for a knee replacement with fifty years of outcome data behind it. That is not a reason never to do it. It is a reason to price the risk honestly.

Cheaper paths worth checking first

• ClinicalTrials.gov. Registered trials are frequently free to participants and are where the credible evidence is generated.
• Ask about cash discounts. Many clinics discount 10–20% for payment without financing, because financing costs them a merchant fee.
• Get a second opinion from a physician with no financial interest in the procedure — an orthopaedic surgeon, a rheumatologist, or your primary care doctor.
• Compare against the conventional option. For knee osteoarthritis, physical therapy, weight management and corticosteroid or hyaluronic acid injections are cheaper, covered by insurance, and better studied.

Sources

1. Contextual effects of mesenchymal stem cell injections for knee osteoarthritis: systematic review and meta-analysis of randomised controlled trials. Frontiers in Medicine, 2025.
2. Consumer Financial Protection Bureau — reports on medical credit cards and deferred interest products.
3. US Food and Drug Administration — Approved Cellular and Gene Therapy Products.

---